Adalimumab-Ryvk
2 NDCs across 1 manufacturer|0 Generic,2 Brand
Adalimumab-Ryvk is used to treat juvenile arthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, crohn disease and hidradenitis suppurativa, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
In 2024, Medicare Part D spent $574K on Adalimumab-Ryvk across 440 claims for 159 beneficiaries.
Adalimumab-Ryvk is available as 2 NDCs from 1 manufacturer (0 generic, 2 brand), with NADAC prices from $493.62 to $493.62 per EA. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
2
0G / 2B
Manufacturers
1
competing in market
Price Spread
$493.62 – $493.62
per EA
7d Activity
avg +0.1% WoW · of 2 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
1 manufacturer producing ADALIMUMAB-RYVK
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
SIMLANDI(CF) 40 MG/0.4 ML AUTOINJECTOR | $493.6164 per EA | +0.14% |
SIMLANDI(CF) 40 MG/0.4 ML AUTOINJECTOR | $493.6164 per EA | +0.14% |
Frequently Asked Questions
What is Adalimumab-Ryvk used to treat?
Adalimumab-Ryvk is used to treat juvenile arthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, crohn disease and hidradenitis suppurativa, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Adalimumab-Ryvk?
In 2024, Medicare Part D spent $574K on Adalimumab-Ryvk across 440 claims for 159 beneficiaries.
How many Adalimumab-Ryvk products are on the market?
The Adalimumab-Ryvk drug market contains 2 NDCs from 1 manufacturer — 0 generic and 2 brand products.
What is the price range for Adalimumab-Ryvk?
NADAC reference prices for Adalimumab-Ryvk range from $493.6164 to $493.6164 per EA.
Which manufacturers make Adalimumab-Ryvk?
1 manufacturer lists Adalimumab-Ryvk in NADAC. Ranked by number of NDCs, the largest are Teva Pharmaceuticals USA Inc. (2).
How has the price of Adalimumab-Ryvk changed recently?
Over the past 7 days, 2 Adalimumab-Ryvk NDCs rose and 0 fell, with a market-wide average change of +0.1%.